

PROVINCIAL FUNDING SUMMARY

Pertuzumab (Perjeta-Herceptin Combo Pack) for Metastatic Breast Cancer (pCODR 10018)

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: Aug 19, 2013

This information is current as of November 9, 2018.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2013	With trastuzumab and docetaxel; ECOG 0-1; first line treatment of HER-2 positive unresectable locally recurrent or metastatic breast cancer. Patients may have received trastuzumab in the neoadjuvant or adjuvant setting but must be relapse free for 6 months; adequate hematology and renal and hepatic function; no clinically significant cardiac disease. A BCCA Compassionate Access Program request must be approved.
AB	Funded	Dec 19, 2013	In combination with trastuzumab and a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within 6 months of receiving trastuzumab in the adjuvant setting.
SK	Funded	Nov 25, 2013	In combination with a taxane and Trastuzumab (Herceptin) for the treatment of patients with HER-2 positive unresectable locally recurrent or metastatic (advanced) breast cancer who have not received prior anti-HER2 therapy or chemotherapy for advanced disease, or who have had a relapse-free interval of at least 6 months from anti-HER2 therapy given in the neoadjuvant or adjuvant setting and who have an ECOG performance status of 0 or 1. After 6 to 8 cycles of combination therapy with taxane, Trastuzumab and Pertuzumab and evidence of disease response, maintenance therapy with the combination of Trastuzumab and Pertuzumab may be continued until disease progression.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
MB	Funded	Mar 14, 2014	<p>For the 1st line treatment of patients with:</p> <ul style="list-style-type: none"> •Unresectable, locally recurrent or metastatic breast cancer, AND •HER-2 positive disease (defined as a 3+ score on immunohistochemistry or 2+ score and a positive FISH test), AND •A Left Ventricular Ejection Fraction (LVEF) of 50% or better, AND •An Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less.
ON	Funded	Nov 25, 2013	<p>For the treatment of unresectable Locally Recurrent or Metastatic Breast Cancer where the patient meets the following criteria:</p> <ul style="list-style-type: none"> ▪ For use in combination with a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer with an ECOG status of 0 or 1, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. <p>Funded dose: Loading dose of pertuzumab 840mg and trastuzumab 8mg/kg, followed every 3 weeks thereafter by a dose pertuzumab 420mg and trastuzumab 6mg/kg, until disease progression or unmanageable toxicity</p> <p>Notes:</p> <ul style="list-style-type: none"> ▪ HER2 positive tumour status is confirmed either by IHC (score of 3+) and/or FISH/SISH/ISH (ratio of ≥ 2). A copy of the complete surgical pathology report must be provided to CCO. The results of the FISH/ SISH/ISH test must also be provided if the IHC test result is equivocal. ▪ The patient must have a baseline left ventricular ejection fraction (LVEF) of $\geq 50\%$ (as determined by a MUGA scan or ECHO). It is recommended that a MUGA scan or ECHO be repeated every 3 months during treatment to ensure that the LVEF is within the institution’s normal limits. ▪ Pertuzumab is funded when given in combination with trastuzumab and a taxane. If the taxane is discontinued (e.g., after 6-8 cycles or due to unmanageable toxicity), continued treatment with pertuzumab-trastuzumab will be funded provided there is no evidence of disease progression while on treatment. ▪ If the time between two sequential infusions is 6 weeks or more, re-load with an initial dose of 840mg pertuzumab and 8mg/kg trastuzumab, followed every 3 weeks thereafter by a dose of 420mg pertuzumab and 6mg/kg trastuzumab.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NS	Funded	Jun 23, 2014	In combination with trastuzumab and a taxane for patients with HER2 positive + advanced/incurable MBC (ECOG PS 0-1) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Patients may be eligible for combination therapy with a ≥ 6 month disease-free interval following completion of adjuvant trastuzumab.
NB	Funded	Apr 1, 2014	For use in combination with trastuzumab and a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer with an ECOG status of 0 or 1, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. Patients who have received trastuzumab in the neoadjuvant or adjuvant setting must be relapse free for at least 6 months
NL	Funded	Apr 1, 2014	For the 1st line treatment of patients with: <ul style="list-style-type: none"> • Unresectable, locally recurrent or metastatic breast cancer, AND • HER-2 positive disease (defined as a 3+ score on immunohistochemistry or 2+ score and a positive FISH test), AND • A Left Ventricular Ejection Fraction (LVEF) of 50% or better, AND • An Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less.
PEI	Funded	Apr 27, 2015	For the palliative treatment of patients with HER2-positive unresectable locally recurrent or metastatic breast cancer with an ECOG status of 0 or 1, who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.